Dianthus Therapeutics DNTH EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's EPS (diluted)?
- Dianthus Therapeutics (DNTH) reported EPS (diluted) of -$0.85 in Q1 2026.
- How has Dianthus Therapeutics's EPS (diluted) changed year-over-year?
- Dianthus Therapeutics's EPS (diluted) decreased by 3.7% year-over-year, from -$0.82 to -$0.85.
- What is the long-term trend for Dianthus Therapeutics's EPS (diluted)?
- Over 2 years (2021 to 2024), Dianthus Therapeutics's EPS (diluted) has grown at a 41.7% compound annual growth rate (CAGR), from -$1.30 to -$2.61.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.